Cognitive outcome and gamma noise power unrelated to neuregulin 1 and 3 variation in schizophrenia by Díez, Á et al.
Díez et al. Annals of General Psychiatry 2014, 13:18
http://www.annals-general-psychiatry.com/content/13/1/18PRIMARY RESEARCH Open AccessCognitive outcome and gamma noise power
unrelated to neuregulin 1 and 3 variation in
schizophrenia
Álvaro Díez1, Clara Cieza-Borrella2,3, Vanessa Suazo2,4, Rogelio González-Sarmiento2,3, Sergi Papiol5,6
and Vicente Molina2,4,7,8*Abstract
Background: Neuregulins are a family of signalling proteins that orchestrate a broad range of cellular responses.
Four genes encoding Neuregulins 1–4 have been identified so far in vertebrates. Among them, Neuregulin 1 and
Neuregulin 3 have been reported to contribute to an increased risk for developing schizophrenia. We hypothesized
that three specific variants of these genes (rs6994992 and rs3924999 for Neuregulin 1 and rs10748842 for
Neuregulin 3) that have been related to this illness may modify information processing capacity in the cortex,
which would be reflected in electrophysiological parameters (P3b amplitude or gamma noise power) and/or
cognitive performance.
Methods: We obtained DNA from 31 patients with schizophrenia and 23 healthy controls and analyzed NRG1 rs6994992,
NRG1 rs3924999 and NRG3 rs10748842 promoter polymorphisms by allelic discrimination with real-time polymerase chain
reaction (PCR). We compared cognitive outcome, P300 amplitude parameters and an electroencephalographic measure
of noise power in the gamma band between the groups dichotomized according to genotype.
Results: Contrary to our hypothesis, we could not detect any significant influence of variation in Neuregulin 1/Neuregulin
3 polymorphisms on cognitive performance or electrophysiological parameters of patients with schizophrenia.
Conclusions: Despite our findings, we cannot discard that other genetic variants and, more likely, interactions between
those variants and with genetic variation related to different pathways may still influence cerebral processing in
schizophrenia.
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It is possible that the link between genetic variation in
neuregulin (NRG) and the increased risk of developing
schizophrenia could be established through the influence
NRG has on the regulation of distributed cerebral activity.
NRGs are a family of signalling proteins containing an
epidermal growth factor (EGF)-like domain that activates
ErbB receptor-tyrosine kinases, which orchestrate a broad
range of cellular responses [1-3]. Among them, Neuregu-
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unless otherwise stated.migration and maturation of gamma-Aminobutyric acid
(GABA) interneurons [4]. The influence attributed to
NRG1-ErbB4 signaling network may have relevant con-
sequences on information processing in the brain, as
suggested by the enhancing effect NRG1 displayed on
gamma oscillations [5].
Genetic variation in NRG1 was associated to an in-
creased risk for developing schizophrenia [6]. Among the
several markers in this gene, the single-nucleotide poly-
morphism (SNP) rs6994992 (SNP8NRG243177) in the pro-
moter region is particularly interesting because of its effect
on the expression levels of type-IV NRG1 in human post-
mortem brain samples and in luciferase in vitro assays
[7,8]. Other genetic variants related to NRG1 have been as-
sociated to schizophrenia, such as the non-synonymousd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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exon E344/E178 (Ig domain), has been associated to higher
latency of the P300 potential [10].
Less information is available on the biological functions
and possible relevance of Neuregulin 3 (NRG3) for mental
illness. However, it is well established that NRG3 is a spe-
cific ligand for ErbB4 [11] and plays an outstanding role in
the development of the cerebral cortex [12]. Four main clas-
ses of NRG3 are generated by alternative splicing [13]. Gen-
etic variation in NRG3 (1.1 Mb, chr.10q23.1), rs10748842 at
intron 1, has also been reported to increase the risk for
schizophrenia and to exert a functional effect on the expres-
sion of class II and III NRG3 isoforms [13].
Among the possible electrophysiological correlates for
genetic variation in NRG, we can highlight the P300 po-
tential amplitude and cortical noise power. Cortical noise
power refers to the amount of scalp-recorded power not
temporally locked to stimuli, quantified as the difference
in each band between the mean power of single trials and
the power magnitude in the averaged potential [14,15].
P3b amplitude decrease and gamma noise power excess
have been previously reported in schizophrenia, the latter
inversely correlated to cognitive performance and directly
to negative symptoms [16-18].
We hypothesized that NRG variants (i.e., rs6994992
and rs3924999 for NRG1 and rs10748842 for NRG3)
may modify the information processing capacity in the
cortex, which would be reflected in electrophysiological
parameters (P3b amplitude or gamma noise power) and/
or cognitive performance.
Methods
We included 31 patients with paranoid schizophrenia
(DSM-IV-TR criteria) and 23 healthy controls (HC). This
sample partly overlaps with that of our previous reports
on noise power in schizophrenia [16,17].
The schizophrenia cases included 10 stable, treated in
the long-term, and 21 untreated cases who received a
minimal treatment prior to the electroencephalographic
(EEG) examination (minimally treated patients; 12 males),
of which 12 were first episodes (7 males). During the pre-
ceding year, the stable patients had been treated with ris-
peridone (7 cases (2 to 6 mg/day)) or olanzapine (3 cases
(5 to 15 mg/day)). Doses and drugs were unchanged during
the 3 months preceding EEG recordings. Prior to their in-
clusion, minimally treated patients had not received any
previous treatment (first episode patients) or they had
dropped their medications for a period longer than
1 month. Owing to an acute psychotic state of these pa-
tients prior to inclusion, we administered a small amount
of haloperidol (2 to 4 mg) 2 days before the EEG study,
with a wash-out period of approximately 24 h before EEG.
The objective was to minimize the likely bias of only in-
cluding patients able to cooperate with the EEG recordingduring an acute psychotic episode. As we reported else-
where [16,17], this treatment had no significant effect on
gamma noise power measurements.
We scored the clinical status of the patients using
the Positive and Negative Syndrome Scale (PANSS) [19].
Marital status was stratified into single (single, divorced,
separated) or living in couple, and employment status as
employed (currently studying or working) or unemployed
(looking for a job or retired for health reasons). Education
was quantified as completed academic courses; the num-
ber of years within the education system since the first of-
ficial academic year (usually at 6 years old) until the last
completed course before dropping out of the system.
We recruited HC through newspaper advertisements
and remunerated their cooperation. They were previously
assessed using a semi-structured psychiatric interview by
one investigator (VM) to discard major psychiatric ante-
cedents (personal or familial) and treatments.
The exclusion criteria included intelligence quotient
(IQ) below 70; a history of any neurological illness; cra-
nial trauma with loss of consciousness; past or present
substance abuse, except nicotine or caffeine; the pres-
ence of any other psychiatric process or treatment and
treatment with drugs known to act on the central ner-
vous system. Toxic use was discarded in patients and
HC with the information gathered in the interview and a
urinalysis.
We obtained written informed consent from the pa-
tients and HC after providing full written information.
The research board (University Hospital of Salamanca) en-
dorsed the study according to The Code of Ethics of the
World Medical Association (Declaration of Helsinki).
Cognitive assessment
We acquired cognitive assessment using the direct scores
from the following subscales of the Spanish version of Brief
Assessment in Cognition in Schizophrenia Scale (BACS)
[20], administered by trained researchers (VS, ÁD): verbal
memory (words list learning), working memory (digit
span), motor speed (token motor task), verbal fluency (cat-
egories), attention and processing speed (symbol coding),
and executive function/problem solving (tower of London).
We used the Spanish version of the Wechsler Adult
Intelligence Scale 3rd Edition (WAIS-III) [21] to assess IQ.
EEG methods
The EEG methods have been reported in detail elsewhere
[16,17]. Essentially, EEG recordings were performed dur-
ing an odd-ball task in which P3a and P3b were elicited
and measured in the Pz site (see Additional file 1 for de-
tails). The EEG was recorded by the Brain Vision® (Brain
Products GmbH; Munich, Germany) equipment from 17
tin electrodes mounted in an electrode cap (Electro-Cap
International, Inc.; Eaton, OH, USA), impedance kept
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electrode and re-referenced off-line to the electrodes' aver-
age activity [22]. The sampling rate was 250 Hz, and the
signal was recorded continuously. We selected noise
power values at F3, F4, P3 and P4 electrodes for the ana-
lysis according to our a priori hypothesis. See Additional
file 1 for detailed information on EEG recording.
For quantitative event-related EEG analysis, the re-
corded signals (−50 to 600 ms post-stimulus, target con-
dition) were submitted to specific band filtering and
spectrum analysis using a fast Fourier transform yielding
spectral values. The absolute magnitude (averaged total
power) in gamma band (35 to 45 Hz) was computed and
expressed in μV2.
As described in previous articles [16,17], we calculated
noise magnitude, which is subsequently denoted as ‘noise
power’. This calculation was based on signal-to-noise ratio
(SNR), a measure of the quality of the EEG signal applied
to each band; it is calculated using the Brain Vision® soft-
ware (Brain Products GmbH; Munich, Germany) [23]
for the time window from −50 to 600 ms for the target
stimuli.
For every individual participant, band and electrode,
we calculated the averaged noise power from the already
extracted average total power (the sum of the signal and
noise power) and SNR (the average signal power quo-
tient divided by the average noise power) using the fol-
lowing formula:
Avg noise power ¼ Avg total power
SNRþ 1
This way, a quantification of the noise part of the ac-
tivity related to the event is approximated and ‘noise’ is
equivalent with activity that is not time-locked to the
stimuli (see Additional file 1 for details).
Genetic methods
DNA extraction
High molecular weight DNA obtained from peripheral
leukocyte blood was isolated using standard procedures
with proteinase K and phenol-chloroform purification.
We extracted buccal cells using simple and sterile
swabs, without medium (Aptaca, Canelli, Italy). The pro-
cedure for the DNA extraction was similar to the proto-
col for obtaining DNA from peripheral blood except for
the proteinase K incubation, which in this case was
longer.
Some of the samples extracted from buccal cells have
shown a very low DNA concentration. In these cases, we
amplified genomic DNA with DNA IllustraTM Amplica-
tion GenomiPhi V2 Kit (GE Healthcare, Buckinghamshire,
UK).Allelic discrimination by real-time PCR
The analysis of NRG1 rs6994992, NRG1 rs3924999 and
NRG3 rs10748842 promoter polymorphisms was carried
out using allelic discrimination with real-time polymerase
chain reaction (PCR). The final volume of the reaction con-
sisted of 10 μl and we used commercial mixtures of primers
and TaqMan MGB® probes (C_22019_10, C_359159_10
and C_1266043_10, respectively) with the sequences VIC:
AAGCACCATGCAGGGTTCAAGTGAACGTATACTGG
AGGCCAGACCTGCCCA and FAM: AAGCACCATG
CAGGGTTCAAGTGAATGTATACTGGAGGCCAGACC
TGCCCA for the first polymorphism; VIC: TTTCT
TCTTTTAGCCTTGCCTCCCCAATTGAAAGAGATGA
AAAGCCAGGAA and FAM: TTTCTTCTTTTAGCCTT
GCCTCCCCGATTGAAAGAGATGAAAAGCCAGGAA
for the second one; and VIC: TTGCATTGTGAGAGGC
TCTGAGTAACTTATGATAAATAATGAAATGCTGTT
and FAM: TTGCATTGTGAGAGGCTCTGAGTAATT
TATGATAAATAATGAAATGCTGTT for the third (Ap-
plied Biosystems, Foster City, CA, USA). We used Taq-
Man® Universal PCR Master Mix No AmpErase® UNG
(Applied Biosystems, Foster City, CA, USA) containing
the DNA polymerase. The amplification program had a
denaturing temperature of 94°C, annealing of 60°C and ex-
tension of 72°C for 1 min each during 40 cycles.
Statistical analyses
By using Chi squared test or Student's t test for inde-
pendent samples when appropriate, we compared demo-
graphic scores between groups. We also used Student's t
test for comparing neurocognitive and neurophysio-
logical parameters between patients and HC groups.
We studied the possible effect of long-term illness and
medication over cognition and neurophysiology by com-
paring chronic and minimally treated patients' outcome
using a non-parametrical test (Mann-Whitney's U test).
In order to test the study's main hypotheses (differ-
ences in cognition, gamma noise power and P300 pa-
rameters related to genetic variation), we dichotomized
the variable rs6994992 into carriers (T+) or non-carriers
(T−) of this risk allele (i.e., TT and TC group vs. CC
group). Variable rs3924999 variation was dichotomized
into carriers and non-carriers of the A allele (AA and
AG vs. GG homozygous). As for NRG3 rs10748842, our
sample only included TT and CT participants.
We used Mann-Whitney's U tests to compare total IQ
and BACS scores, P300 amplitude (P3a and P3b) and
gamma noise power at F3, F4, P3 and P4 electrodes be-
tween the groups dichotomized according to their geno-
type. Moreover, using the same test, we compared each
group of patients with the HC carrying the same vari-
ation. We repeated these analyses only including the
minimally treated patients' subgroup in order to discard
the effects of treatment and chronicity on the arising
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results yielded by these secondary analyses were only con-
sidered as informational. Given the number of planned
comparisons (gamma noise power in four electrodes, P3a
and P3b amplitudes and 6 cognitive variables × 3 genetic
variants = 36 comparisons), we set the level of corrected
significance at p = 0.001 (0.05 × 36 = 0.00138). Accord-
ingly, trend level was set at p = 0.006. These restrictions
were not applied to the initial comparisons between pa-
tients and HC that did not consider genotype because
these comparisons were descriptive and did not explore
the study's hypothesis.
Finally, taking into account our limited sample size, we
performed a power analysis for each of the comparisons
involving genetic variants (Bonferroni-corrected signifi-
cance level of p = 0.001; see Additional file 1 for details).
Results
Patients vs. HC comparisons
There were no significant differences in age (t = 1.306,
df = 52, p = 0.197) or sex distribution (χ2 = 0.013, df = 1,Table 1 Sociodemographic, clinical, cognitive and
neurophysiological values in patients and healthy controls
All patients
(N = 31)
Healthy controls
(N = 23)
Age 36.42 (12.07) 31.91 (13.14)
Sex (M:F) 18:13 13:10
Marital status (% singles)** 96.30 68.18
Employment status (% employed)* 42.31 77.27
Education (completed courses) 10.94 (3.81) 11.50 (3.00)
Total IQ** 81.68 (14.20) 104.00 (13.09)
PANSS positive 20.25 (4.33) N/A
PANSS negative 19.68 (5.54) N/A
PANSS total 75.46 (12.11) N/A
BACS - verbal memory*** 36.18 (12.38) 54.87 (7.68)
BACS - working memory*** 16.93 (5.16) 22.17 (3.77)
BACS - motor speed*** 50.24 (15.52) 64.61 (14.85)
BACS - verbal fluency*** 16.41 (4.76) 25.48 (4.84)
BACS - processing speed*** 37.32 (14.72) 58.57 (12.24)
BACS - problem solving*** 12.33 (6.12) 17.52 (3.10)
P3b valid segments (n) 44.87(21.05) 57.13(24.48)
Pz amplitude S2 (P3a; μV) 0.870 (1.125) 1.297 (0.981)
Pz amplitude S3 (P3b; μV)** 0.815 (1.587) 1.935 (0.910)
Gamma noise power F3 (μV2) 0.012 (0.012) 0.009 (0.015)
Gamma noise power F4 (μV2) 0.012 (0.013) 0.008 (0.009)
Gamma noise power P3 (μV2)** 0.012 (0.009) 0.006 (0.004)
Gamma noise power P4 (μV2)** 0.012 (0.007) 0.007 (0.004)
Data specified as percentage (%), simple distribution or pertaining to Mean
(S.D.); *p < 0.05; **p < 0.01; ***p < 0.001 (Chi square test or Student's t test
when corresponding); N/A, not applicable.p = 0.910) between patients and HC. Marital (χ2 = 7.014,
df = 1, p = 0.008) and employment status (χ2 = 5.994, df =
1, p = 0.014) were significantly different between groups.
IQ and all BACS scores were significantly lower in patients
(Table 1).
Patients showed a significant reduction in P3b ampli-
tude (t = 3.029; df = 52; p = 0.004) and a significantly
higher gamma noise power at P3 (t = 2.971; df = 52; p =
0.004) and P4 (t = 2.669; df = 52; p = 0.010) electrodes in
comparison to HC (Table 1).
Chronic vs. minimally treated patients
Chronic patients were significantly older and had more
negative symptoms than minimally treated patients (p <
0.01). There were no significant differences between these
groups in the main cognitive and neurophysiological mea-
sures (Additional file 1: Table S1).
Genetic-related differences
NRG1 rs6994992
There were 21T + (TT homozygous or TC heterozygous)
and 10T − (CC) in the patient group (13 and 8 respect-
ively for minimally treated patients). In the HC group,
there were 12T + and 11T−. This difference was not sig-
nificant (χ2 = 1.347, df = 1, p = 0.246).
There were no significant differences in cognitive per-
formance between T + vs. T − patients or between T + and
T −HC, even at uncorrected p < 0.05 level (Table 2).
Power values were low in all cases (P < 18%) (Additional
file 1: Table S3).
T + and T − patients showed worse cognitive performance
than the corresponding T+ and T −HC, reaching the re-
quired level of significance (p < 0.001; P > 96%) for total IQ
(T + patients vs. T +HC), verbal memory (T− patients vs.
T −HC), verbal fluency (T + patients vs. T +HC and T−
patients vs. T −HC) and processing speed (T− patients vs.
T −HC) (Table 2 and Additional file 1: Table S3); in the
minimally treated patients considered alone, the level of sig-
nificance held up at p < 0.001 (Additional file 1: Table S2).
Gamma noise power was not significantly different be-
tween T + and T − patients or between T + and T −HC,
with power values always below 7% (Table 2 and Additional
file 1: Table S3).
T + and T − patients did not show significant differ-
ences in P3a, P3b or gamma noise power at any elec-
trode site in comparison to T + and T −HC, with power
value below 26% (Additional file 1: Table S3).
NRG1 rs3924999
There were 18 A + (AA or AG) and 13 A − (GG) in the pa-
tient group (12 and 9 respectively for minimally treated
patients). In the HC group, there were 16 A + and 7 A−.
This difference was non-significant (χ2 = 0.749, df = 1,
p = 0.387).
Table 2 Sociodemographic, clinical, cognitive and neurophysiological values according to NRG1 rs6994992 and rs3924999, and NRG3 rs10748842 genotypes
NRG1 rs6994992 NRG1 rs3924999 NRG3 rs10748842
Patients Healthy controls Patients Healthy controls Patients Healthy controls
T + (N = 21) T − (N = 10) T + (N = 12) T − (N = 11) A + (N = 18) A − (N = 13) A + (N = 16) A − (N = 7) C + (N = 8) C − (N = 23) C + (N = 4) C − (N = 19)
Age (years) 36.24 (12.26) 36.80 (12.33) 33.92 (14.86) 29.73 (11.25) 35.50 (14.02) 37.69 (9.10)* 33.69 (13.42) 27.86 (12.44) 35.38 (8.40) 36.78 (13.26) 40.25 (21.22) 30.16 (10.82)
Total IQ 82.16 (15.85)*** 80.67 (10.62)** 101.92 (11.91) 106.27 (14.50) 81.13 (14.74)*** 82.42 (14.04)** 104.19 (14.10) 103.57 (11.47) 83.67 (10.58)* 81.14 (15.20)*** 106.25 (14.34) 103.53 (13.19)
PANSS positive 20.05 (3.56) 20.75 (6.14) N/A N/A 20.94 (4.48) 19.33 (4.14) N/A N/A 19.86 (5.11) 20.38 (4.18) N/A N/A
PANSS negative 20.10 (5.77) 18.63 (5.13) N/A N/A 17.69 (5.10)* 22.33 (5.14) N/A N/A 20.29 (7.89) 19.48 (4.75) N/A N/A
PANSS total 75.75 (11.00) 74.75 (15.37) N/A N/A 71.88 (11.62) 80.25 (11.48) N/A N/A 75.00 (11.66) 75.62 (12.53) N/A N/A
BACS verbal
memory
35.44 (14.14)** 37.50 (8.90)*** 51.75 (8.71) 58.27 (4.69) 37.53 (13.30)*** 34.09 (11.09)* 55.50 (6.61) 53.43 (10.18) 34.86 (14.04) 36.62 (12.12)*** 50.25 (9.91) 55.84 (7.07)
BACS working
memory
16.33 (5.82)** 18.11 (3.48)* 22.17 (4.34) 22.18 (3.25) 17.13 (5.15)** 16.67 (5.38) 22.50 (3.18) 21.43 (5.09) 16.83 (4.54)* 16.95 (5.43)** 23.00 (1.41) 22.00 (4.11)
BACS motor speed 48.63 (17.03)* 53.30 (12.37) 65.33 (15.69) 63.82 (14.60) 52.18 (14.63) 47.50 (16.95)** 60.75 (14.23) 73.43 (13.10) 50.43 (13.76) 50.18 (16.34)** 59.50 (23.74) 65.68 (12.98)
BACS verbal
fluency
16.32 (5.38)*** 16.60 (3.53)*** 25.17 (5.37) 25.82 (4.42) 16.12 (5.13)*** 16.83 (4.34)* 27.13 (3.38) 21.71 (5.79) 17.43 (3.60)** 16.09 (5.10)*** 27.75 (4.35) 25.00 (4.91)
BACS processing
speed
38.33 (17.47)** 35.50 (8.25)*** 57.17 (11.47) 60.09 (13.42) 38.24 (16.74)*** 35.91 (11.53)** 60.13 (13.02) 55.00 (10.21) 37.86 (14.46) 37.14 (15.15)*** 49.75 (5.44) 60.42 (12.54)
BACS problem
solving
13.41 (5.48) 10.50 (7.00)* 16.92 (3.06) 18.18 (3.16) 11.50 (6.20)** 13.55 (6.09) 17.25 (3.32) 18.14 (2.67) 12.86 (5.61) 12.15 (6.42)** 15.75 (3.77) 17.89 (2.92)
P3b valid segments
(n)
45.76 (18.53) 43.00 (26.62) 53.25 (25.03) 61.36 (24.33) 43.00 (21.01) 47.46 (21.68) 54.94 (25.72) 62.14 (22.41) 47.38 (27.51) 44.00 (18.99) 54.00 (17.42) 57.79 (26.07)
Pz amplitude S2
(P3a; μV)
0.968 (1.127) 0.666 (1.154) 1.485 (0.762) 1.093 (1.179) 0.929 (1.193) 0.789 (1.066) 1.210 (0.982) 1.497 (1.025) 0.707 (1.052) 0.927 (1.167) 1.114 (0.691) 1.336 (1.043)
Pz amplitude S3
(P3b; μV)
0.735 (1.509)** 0.983 (1.814) 2.033 (0.680) 1.827 (1.136) 0.769 (1.449)* 0.878 (1.821)* 1.623 (0.873) 2.647 (0.532) 0.623 (1.553)* 0.882 (1.628)* 1.915 (0.400) 1.939 (0.993)
Gamma Noise
Power F3 (μV2)
0.012 (0.012) 0.011 (0.011) 0.007 (0.003) 0.013 (0.022) 0.014 (0.014)* 0.009 (0.005) 0.007 (0.005) 0.016 (0.026) 0.013 (0.012)* 0.011 (0.012) 0.004 (0.000) 0.011 (0.016)
Gamma Noise
Power F4 (μV2)
0.009 (0.006) 0.018 (0.021) 0.006 (0.003) 0.011 (0.013) 0.015 (0.017) 0.007 (0.003) 0.007 (0.004) 0.012 (0.016) 0.013 (0.016) 0.011 (0.012) 0.005 (0.001) 0.009 (0.010)
Gamma Noise
Power P3 (μV2)
0.011 (0.009)* 0.015 (0.010)** 0.006 (0.003) 0.007 (0.004) 0.013 (0.010)** 0.012 (0.008) 0.006 (0.004) 0.006 (0.002) 0.013 (0.009)* 0.012 (0.010)** 0.004 (0.002) 0.007 (0.004)
Gamma Noise
Power P4 (μV2)
0.012 (0.008)* 0.011 (0.005) 0.007 (0.005) 0.007 (0.004) 0.013 (0.009)** 0.009 (0.003) 0.007 (0.004) 0.009 (0.006) 0.011 (0.006) 0.012 (0.008)* 0.005 (0.004) 0.008 (0.005)
No within-group significant differences were detected between patients or HC subgroups classified according to their genotype. Differences between patients and HC with the same SNP variation are displayed in the
Patients column. Data exhibited as Mean (S.D.); *p < 0.05; **p < 0.01; ***p < 0.001; Significant results after Bonferroni correction (p < 0.00138) are in italics (Mann-Whitney's U test); N/A, not applicable.
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formance between A + and A − patients or between A +
and A −HC, even at uncorrected p < 0.05 level (Table 2).
Power values were below 25% in all cases (Additional file
1: Table S3).
A + patients showed significantly worse cognitive per-
formance than the corresponding A + HC (p < 0.001;
P > 83%) for total IQ, verbal memory, verbal fluency and
processing speed (Table 2 and Additional file 1: Table S3).
These differences also held up for the minimally treated
patients considered alone (Additional file 1: Table S2).
There were no significant differences in gamma noise
power or in P3b and P3a amplitudes between A + and A −
patients or between A + and A −HC, with power values al-
ways below 16% (Table 2 and Additional file 1: Table S3).
A + and A − patients did not show significant differ-
ences in P3a, P3b or gamma noise power at any elec-
trode site in comparison to A + and A −HC, with power
value below 36% (Additional file 1: Table S3).
NRG3 rs10748842
There were 8 C + (only CT heterocygotes), and 23 C −
(TT homocygotes) in the patient group (5 and 16 re-
spectively for minimally treated patients). In the HC
group, there were 4 C + and 19 C−. This difference was
not significant (χ2 = 0.541, df = 1, p = 0.462).
There were no significant differences in cognitive per-
formance between subgroups of patients depending on
their genotype, with power values always below 13%
(Table 2 and Additional file 1: Table S3).
C − patients showed significantly lower total IQ, verbal
memory, verbal fluency and processing speed scores
than C −HC (p < 0.001; P > 98%; Table 2 and Additional
file 1: Table S3). This result was also found in the com-
parison between minimally treated patients and HC
(Additional file 1: Table S2).
There were no significant differences between C + and
C − patients in gamma noise power or P3b and P3a am-
plitudes (Table 2). Power values were low (P < 8%) in all
cases (Additional file 1: Table S3).
C + and C − patients did not show significant differ-
ences in P3a, P3b or gamma noise power at any elec-
trode site in comparison to C + and C −HC, with power
value below 26% (Additional file 1: Table S3).
Discussion
We examined possible abnormal cerebral information
processing in a group of chronic and minimally treated
patients with schizophrenia using electrophysiological
and cognitive data of interest and the association with
genetic variation in three SNPs related to increased risk
of suffering this disease.
We could not detect any significant influence of vari-
ation in NRG1/NRG3 polymorphisms on the cognitiveperformance of patients with schizophrenia. This negative
finding is coherent with previous data, which did not show
an association between cognition and genetic variation in
NRG in schizophrenia [24]. The variety of functions sub-
served by NRG in the brain's development suggests the
possibility that other SNP or haplotypes related to NRG1
and/or ERBB4 may be associated to cognitive deficit and/
or disorganized cortical activity in schizophrenia [25,26].
Variation in NRG polymorphisms included in our study
may have a significant effect on other relevant functional
parameters in schizophrenia that were not assessed in our
study: the T allele for rs6994992 has been associated to
prepulse inhibition deficits [27], fronto-temporal activa-
tion and cognitive deficits [28], and white matter integrity
[29] in schizophrenia.
We did not find an association between electrophysio-
logical parameters of activation (P3b amplitude or gamma
noise power) and any of the explored genetic variation in
NRG, in spite of previous suggestive evidence obtained
with functional magnetic resonance (fMRI) in relation to
rs6994992 variant [28]. In the abovementioned study, the
authors compared differences in task-related activation,
while our aim was to compare the amount of gamma ac-
tivity unrelated to task performance. Therefore, it seems
possible that rs6994992 variant may have an effect on
task-related activation but not on basal activity.
Other NRG variants not included in our study may have
an influence on relevant activation patterns in schizophre-
nia. For example, SNP8NRG221533 (rs35753505) was as-
sociated to a longer latency [30] of the P300 potential in
this illness. In healthy participants, the number of risk al-
leles of rs35753505 variant correlated with hyperactivation
of the frontal gyrus during a working memory test [31]
and other regions during memory encoding [32]. Finally,
NRG1 5′ and 3′ SNPs rs4560751 and rs3802160 polymor-
phisms (likelihood ratio test p = 0.00020) interacted with
schizophrenia, and contributed to inefficient cortical acti-
vation during a working memory task in HC [33]. It could
be interesting to investigate if these polymorphisms have
an effect on EEG variables such as the ones we assessed in
this work.
Epistatic effects may contribute to explain the lack of in-
fluence of the polymorphisms selected in our study on
complex phenotypic features, such as cortical activation
and cognition. Previous findings suggest epistasis between
NRG1 (rs10503929; Thr286/289/294Met) and its receptor
ERBB4 (rs1026882) as well as a three-way interaction with
these two SNPs and AKT1 (rs2494734) [33]. Epistatic ef-
fects may be especially important between genetic varia-
tions concerning NRG1 and, on the other hand, ErbB4
receptors and/or N-methyl-D-aspartic acid (NMDA) trans-
mission [25]. However, one of our study limitations is that
we did not assess possible epistatic interactions between ge-
notypes and cognitive and electrophysiological parameters.
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and medication on cortical processing, which may mask
the interaction with the studied genetic variations. Ac-
cording to our results, chronicity does not seem to alter
patients' cognitive or neurophysiological outcome. How-
ever, even though we attempted to control for this pos-
sible effect by repeating the analyses only including the
minimally treated patients' subgroup, the sample size re-
duction may limit any further conclusions. Finally, our
sample size is limited as evidenced by the power ana-
lyses, especially for the neurophysiological comparisons
between subgroups according to their genetic variants.
Therefore, the absence of differences depending on the
genotypes might be due to type II errors; nevertheless,
this would be contradictory with the similar direction of
the exhibited differences between our patients with any
variant for each genotype and the corresponding HC.
Conclusions
We could not detect any significant influence of vari-
ation in the studied Neuregulin 1 and Neuregulin 3
polymorphisms on cognitive performance or on gamma
noise power magnitudes in patients with schizophrenia.
Variation at these loci may have a significant effect on
other relevant functional parameters not assessed in our
study.
Additional file
Additional file 1: Additional methods and results. This file includes a
description for additional EEG recording methods and analysis (pre-processing,
P3a and P3b calculation, and signal-to-noise ratio), power analysis procedure
and results for the main contrasts, and study results for minimally treated
patients in comparison to chronic patients and healthy controls.
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